Vivione Biosciences set for food safety breakthrough - 500 Beiträge pro Seite
eröffnet am 29.09.13 15:35:44 von
neuester Beitrag 30.04.14 19:21:23 von
neuester Beitrag 30.04.14 19:21:23 von
Beiträge: 23
ID: 1.186.659
ID: 1.186.659
Aufrufe heute: 0
Gesamt: 2.454
Gesamt: 2.454
Aktive User: 0
ISIN: CA9285441056 · Symbol: VBI.H
0,0150
CAD
0,00 %
0,0000 CAD
Letzter Kurs 21.04.17 Toronto
Werte aus der Branche Elektrogeräte
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3000 | +71.367,84 | |
| 25,12 | +39,05 | |
| 0,5900 | +31,11 | |
| 213,40 | +19,99 | |
| 8,9500 | +19,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7508 | -7,99 | |
| 219,00 | -8,76 | |
| 5,0000 | -9,91 | |
| 17,560 | -9,99 | |
| 4,0000 | -33,33 |
Feedback
Story siehe Interview und Homepage.
Total Shares: 36,361,382
http://web.tmxmoney.com/quote.php?qm_symbol=VBI
Homepage:
http://www.vivionebiosciences.com/index.php
Stockhouse:
http://www.stockhouse.com/companies/quote/v.vbi/vivione-bios…
Auszug aus Interview unten:
Third, the company is adequately funded to maintain its current operations and development schedules through 2014 without the addition of any revenue.
First, it’s important to understand that the technological risk in the RAPID-B system has been mitigated because Vivione has spent six years in development with the FDA on the technology with hundreds of thousands of tests completed comparing the RAPID-B system to other available technologies.
Q&A with Vivione Biosciences, LLC (V.VBI), CEO Kevin Kuykendall
http://www.stockhouse.com/Opinion/Interviews/2013/09/27/Vivi…
Kevin, can you tell me about Vivione Biosciences?
Vivione Biosciences, LLC (TSX: V.VBI, Stock Forum) is a life sciences diagnostic company who collaborated with the Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) over six years to develop the RAPID-B system. RAPID-B detects bacterial pathogens and has diverse applicability from food safety to clinical diagnostics. Our business is centered on the commercialization of the new ultra-high performance RAPID-B.
In April, Vivione merged with PACEpartners Inc. What was the significance of this merger for Vivione?
The merger provided two primary benefits, the first being financing of $6 million, which will be utilized to commercialize the RAPID-B system. The second benefit is becoming a publicly traded entity, which gives Vivione the ability to provide transparency and comfort to potential customers regarding the company’s financial stability. RAPID-B is a paradigm shift in the way manufacturers will be able to obtain diagnostic test results. When making a new platform decision, customers will want to ensure they’re dealing with a financially viable entity. The transparency of a public company versus a privately held company provides this capability.
What is the RAPID-B System and how is it disruptive in the food safety market?
RAPID-B is an integrated diagnostic system consisting of hardware, software and wetware that tests bacteria in key environments and provides test results in seven hours or less, including sample preparation. Current competitor diagnostic platforms range from 24 hours to five days.
The RAPID-B system is easy to operate by lab personnel and does not require frequent calibration, making the RAPID-B system more capable of use in real manufacturing environments. Bacteria detection, data collection, and analysis are seamless. Obtaining test results faster will enable food manufacturers to reduce their chemical costs, reduce inventory hold times, and ultimately mitigate their potential recall risks.
What are 2 potential applications of your RAPID-B technology?
The RAPID-B system has broad applicability across many different markets. In food manufacturing, RAPID-B can be utilized to test for E. coli 0157 and Salmonella and provide test results in less than seven hours, including sample preparation time. In clinical applications, RAPID-B can test for the presence of tuberculosis in sputum providing results in less than one hour.
What do you think you could do with the RAPID-B system over time? What would the goals for it be?
We are confident the RAPID-B system will revolutionize the way food manufacturers look at diagnostics. For the first time, food manufacturers will be able to obtain near real time diagnostic results which will enable them to better manage their production processes, inventory and reduce their anti-microbial and other chemical costs. In the clinical diagnostics markets, being able to obtain tuberculosis and other disease test results rapidly will enable faster treatments which will ultimately save lives.
Where are you at with commercialization?
We currently have several reagent products (E. coli 0157, STECs, Salmonella, Vibrio, and TPC (Total Plate Count) available in food safety. We will undertake AOAC and FSIS certifications in 3Q2013 for E. coli 0157 and STECs, with AOAC certification beginning for Salmonella in first quarter 2014.
We also have several sterility and an agriculture product for tomatoes available for immediate use. In the clinical markets, we have completed proof of concepts for tuberculosis diagnosis and are in the process of organizing additional clinical trials which we hope to undertake in the fourth quarter 2014.
What milestones are you hoping to achieve for the next 6 months?
Three key goals for the next six months include AOAC submission for E. coli 0157, STECs, and Salmonella, signing key collaboration agreements with academic institutions and vendors that enable Vivione to develop and prove new assays on the RAPID-B platform, and beginning to drive revenue through commercial sales.
What are 3 things that an Investor needs to know about Vivione?
First, it’s important to understand that the technological risk in the RAPID-B system has been mitigated because Vivione has spent six years in development with the FDA on the technology with hundreds of thousands of tests completed comparing the RAPID-B system to other available technologies.
Second, in third quarter 2013 we began the certification process which will broaden RAPID-B’s applicability in the food safety market and begin driving commercial revenues. We look forward to communicating positive results on this front in early 2014.
Third, the company is adequately funded to maintain its current operations and development schedules through 2014 without the addition of any revenue.
Disclosure: Vivione Biosciences is a Stockhouse client.
Kevin Kuykendall - CEO and Director, Vivione Biosciences Founding Member and CEO of White Energy (Ethanol Producer) and Health2O (Nutraceuticals)
Raised $500MM in White Energy and developed $750MM in Revenue within 36 months
Experienced in both early stage and start-up fund raising for various ventures
Total Shares: 36,361,382
http://web.tmxmoney.com/quote.php?qm_symbol=VBI
Homepage:
http://www.vivionebiosciences.com/index.php
Stockhouse:
http://www.stockhouse.com/companies/quote/v.vbi/vivione-bios…
Auszug aus Interview unten:
Third, the company is adequately funded to maintain its current operations and development schedules through 2014 without the addition of any revenue.
First, it’s important to understand that the technological risk in the RAPID-B system has been mitigated because Vivione has spent six years in development with the FDA on the technology with hundreds of thousands of tests completed comparing the RAPID-B system to other available technologies.
Q&A with Vivione Biosciences, LLC (V.VBI), CEO Kevin Kuykendall
http://www.stockhouse.com/Opinion/Interviews/2013/09/27/Vivi…
Kevin, can you tell me about Vivione Biosciences?
Vivione Biosciences, LLC (TSX: V.VBI, Stock Forum) is a life sciences diagnostic company who collaborated with the Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) over six years to develop the RAPID-B system. RAPID-B detects bacterial pathogens and has diverse applicability from food safety to clinical diagnostics. Our business is centered on the commercialization of the new ultra-high performance RAPID-B.
In April, Vivione merged with PACEpartners Inc. What was the significance of this merger for Vivione?
The merger provided two primary benefits, the first being financing of $6 million, which will be utilized to commercialize the RAPID-B system. The second benefit is becoming a publicly traded entity, which gives Vivione the ability to provide transparency and comfort to potential customers regarding the company’s financial stability. RAPID-B is a paradigm shift in the way manufacturers will be able to obtain diagnostic test results. When making a new platform decision, customers will want to ensure they’re dealing with a financially viable entity. The transparency of a public company versus a privately held company provides this capability.
What is the RAPID-B System and how is it disruptive in the food safety market?
RAPID-B is an integrated diagnostic system consisting of hardware, software and wetware that tests bacteria in key environments and provides test results in seven hours or less, including sample preparation. Current competitor diagnostic platforms range from 24 hours to five days.
The RAPID-B system is easy to operate by lab personnel and does not require frequent calibration, making the RAPID-B system more capable of use in real manufacturing environments. Bacteria detection, data collection, and analysis are seamless. Obtaining test results faster will enable food manufacturers to reduce their chemical costs, reduce inventory hold times, and ultimately mitigate their potential recall risks.
What are 2 potential applications of your RAPID-B technology?
The RAPID-B system has broad applicability across many different markets. In food manufacturing, RAPID-B can be utilized to test for E. coli 0157 and Salmonella and provide test results in less than seven hours, including sample preparation time. In clinical applications, RAPID-B can test for the presence of tuberculosis in sputum providing results in less than one hour.
What do you think you could do with the RAPID-B system over time? What would the goals for it be?
We are confident the RAPID-B system will revolutionize the way food manufacturers look at diagnostics. For the first time, food manufacturers will be able to obtain near real time diagnostic results which will enable them to better manage their production processes, inventory and reduce their anti-microbial and other chemical costs. In the clinical diagnostics markets, being able to obtain tuberculosis and other disease test results rapidly will enable faster treatments which will ultimately save lives.
Where are you at with commercialization?
We currently have several reagent products (E. coli 0157, STECs, Salmonella, Vibrio, and TPC (Total Plate Count) available in food safety. We will undertake AOAC and FSIS certifications in 3Q2013 for E. coli 0157 and STECs, with AOAC certification beginning for Salmonella in first quarter 2014.
We also have several sterility and an agriculture product for tomatoes available for immediate use. In the clinical markets, we have completed proof of concepts for tuberculosis diagnosis and are in the process of organizing additional clinical trials which we hope to undertake in the fourth quarter 2014.
What milestones are you hoping to achieve for the next 6 months?
Three key goals for the next six months include AOAC submission for E. coli 0157, STECs, and Salmonella, signing key collaboration agreements with academic institutions and vendors that enable Vivione to develop and prove new assays on the RAPID-B platform, and beginning to drive revenue through commercial sales.
What are 3 things that an Investor needs to know about Vivione?
First, it’s important to understand that the technological risk in the RAPID-B system has been mitigated because Vivione has spent six years in development with the FDA on the technology with hundreds of thousands of tests completed comparing the RAPID-B system to other available technologies.
Second, in third quarter 2013 we began the certification process which will broaden RAPID-B’s applicability in the food safety market and begin driving commercial revenues. We look forward to communicating positive results on this front in early 2014.
Third, the company is adequately funded to maintain its current operations and development schedules through 2014 without the addition of any revenue.
Disclosure: Vivione Biosciences is a Stockhouse client.
Kevin Kuykendall - CEO and Director, Vivione Biosciences Founding Member and CEO of White Energy (Ethanol Producer) and Health2O (Nutraceuticals)
Raised $500MM in White Energy and developed $750MM in Revenue within 36 months
Experienced in both early stage and start-up fund raising for various ventures
Antwort auf Beitrag Nr.: 45.535.725 von Jon_Schnee am 29.09.13 15:35:44UPDATE: Vivione Biosciences to Take Over Lab Space at Pine Bluff Arsenal
by Mark Carter on Tuesday, May. 8, 2012 11:38 am
http://www.arkansasbusiness.com/article/31449/update-vivione…
by Mark Carter on Tuesday, May. 8, 2012 11:38 am
http://www.arkansasbusiness.com/article/31449/update-vivione…
Achtung: Nearly 60,000,000 shares are outstanding
Wer kennt sich mit der Company aus? Lese mich gerade ein.
Vivione Biosciences (V.VBI) is on trend, accelerating product development
Calgary biotech small cap, Vivione Biosciences Inc. (TSX:V.VBI, Stock Forum) is paddling hard just as a wave appears to be breaking around them, with the announcement that they’ll be partnering up with Kirkegaard & Perry Laboratories Inc. to get their RAPID-B food-borne pathogen detection platform to market.
Vivione (formerly PACE Partners Inc) executives have built their business around commercialization of RAPID-B, and the inclusion of KPL’s Bac-Trace affinity-purified primary antibodies in the system will bring the starting line way closer for the $16 million market cap outfit.
As the company explains it, the promise of RAPID-B is that it has the potential to provide food pathogen detection down to a single cell in as little as seven hours, as opposed to the 48 hours for competing methods.
At a time when billions of dollars are being spent recalling food products on a regular basis when bacterial outbreaks are found in the supply chain, and with the organic and pesticide-free sector experiences a massive growth spurt that makes testing all the more important, the time couldn’t be better for Vivione to emerge with a faster, more efficient, easier to use testing unit – one developed in collaboration with the United States Food & Drug Administration.
“Vivione collaborated with the U.S. Food and Drug Administration’s National Center for Toxicological Research (NCTR) over the past 6 years to accomplish the development and testing of the RAPID-B system,” said Kevin Kuykendall, Chief Executive Officer of Vivione in a press release Wednesday.
“The strategic relationship with KPL enables us to immediately expand our product offerings and get to market much faster by leveraging their leadership expertise in antibody-based reagent production.”
KPL is a veteran outfit with twenty years in the business of providing antibodies for Salmonella, STECs, E. coli, Listeria and Campylobacter, so partnering up brings a high quality consistent component to Vivione’s system.
The announcement of the new collaboration follows similar earlier announcements of a distribution deal with Quip Laboratories, and research collaborations with the University of Arkansas Department of Food Science and Agriculture Center for Food Safety.
The share price for V.VBI settled in at $0.20 at the time of writing, $0.02 up from the 52-week low. Nearly 60,000,000 shares are outstanding.
Read more at http://www.stockhouse.com/companies/bullboard/v.vbi/vivione-…
Wer kennt sich mit der Company aus? Lese mich gerade ein.
Vivione Biosciences (V.VBI) is on trend, accelerating product development
Calgary biotech small cap, Vivione Biosciences Inc. (TSX:V.VBI, Stock Forum) is paddling hard just as a wave appears to be breaking around them, with the announcement that they’ll be partnering up with Kirkegaard & Perry Laboratories Inc. to get their RAPID-B food-borne pathogen detection platform to market.
Vivione (formerly PACE Partners Inc) executives have built their business around commercialization of RAPID-B, and the inclusion of KPL’s Bac-Trace affinity-purified primary antibodies in the system will bring the starting line way closer for the $16 million market cap outfit.
As the company explains it, the promise of RAPID-B is that it has the potential to provide food pathogen detection down to a single cell in as little as seven hours, as opposed to the 48 hours for competing methods.
At a time when billions of dollars are being spent recalling food products on a regular basis when bacterial outbreaks are found in the supply chain, and with the organic and pesticide-free sector experiences a massive growth spurt that makes testing all the more important, the time couldn’t be better for Vivione to emerge with a faster, more efficient, easier to use testing unit – one developed in collaboration with the United States Food & Drug Administration.
“Vivione collaborated with the U.S. Food and Drug Administration’s National Center for Toxicological Research (NCTR) over the past 6 years to accomplish the development and testing of the RAPID-B system,” said Kevin Kuykendall, Chief Executive Officer of Vivione in a press release Wednesday.
“The strategic relationship with KPL enables us to immediately expand our product offerings and get to market much faster by leveraging their leadership expertise in antibody-based reagent production.”
KPL is a veteran outfit with twenty years in the business of providing antibodies for Salmonella, STECs, E. coli, Listeria and Campylobacter, so partnering up brings a high quality consistent component to Vivione’s system.
The announcement of the new collaboration follows similar earlier announcements of a distribution deal with Quip Laboratories, and research collaborations with the University of Arkansas Department of Food Science and Agriculture Center for Food Safety.
The share price for V.VBI settled in at $0.20 at the time of writing, $0.02 up from the 52-week low. Nearly 60,000,000 shares are outstanding.
Read more at http://www.stockhouse.com/companies/bullboard/v.vbi/vivione-…
Antwort auf Beitrag Nr.: 45.535.873 von Jon_Schnee am 29.09.13 16:59:35Das Umfeld stimmt. Jetzt braucht es ein weitsichtiges Management um die Kommerzialisierung schnell voranzutreiben ohne die Company zu sehr zu verwässern.
At a time when billions of dollars are being spent recalling food products on a regular basis when bacterial outbreaks are found in the supply chain, and with the organic and pesticide-free sector experiences a massive growth spurt that makes testing all the more important, the time couldn’t be better for Vivione to emerge with a faster, more efficient, easier to use testing unit – one developed in collaboration with the United States Food & Drug Administration.
At a time when billions of dollars are being spent recalling food products on a regular basis when bacterial outbreaks are found in the supply chain, and with the organic and pesticide-free sector experiences a massive growth spurt that makes testing all the more important, the time couldn’t be better for Vivione to emerge with a faster, more efficient, easier to use testing unit – one developed in collaboration with the United States Food & Drug Administration.
Kurs kommt wieder zurück. Derzeit 0.22 CAD. So bei 0.20 CAD wirds intressant.
Ist jemand investiert oder intressiert an VBI?
Ist jemand investiert oder intressiert an VBI?
Trading Spotlight
Antwort auf Beitrag Nr.: 45.555.165 von Jon_Schnee am 02.10.13 14:54:04So wir sind wieder bei 0.20 CAD. Und somit steigt der Wert höher hinauf auf meiner Watch List.
Vivione Biosciences Inc. Announces Loan Agreement
V.VBI | September 12, 2013
CALGARY, Sept. 12, 2013 /CNW/ - Vivione Biosciences Inc. ("Vivione") (TSXV: VBI) is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Mr. Glenn Smith, a director of Vivione (the "Lender"), whereby the Lender has agreed to provide Vivione with a revolving line of credit facility up to a maximum amount of CDN $1,000,000 for a two-year term (the "Loan"). The Loan will bear interest at a rate of 1% per month on the daily outstanding balance under the Loan, with interest calculated and payable monthly. The Loan is subject to the acceptance of the TSX Venture Exchange.
Pursuant to the terms of the Loan Agreement, Vivione intends to issue and allot to the Lender 400,000 non-transferrable warrants to purchase Class A common shares (the "Bonus Warrants") in the capital of Vivione at an exercise price of $0.35 per share for a two-year term. If the Class A common Shares of Vivione trade on the TSX Venture Exchange at a closing price above $0.42 for 20 consecutive days, the Bonus Warrants will be subject to accelerated expiry, such that the Bonus Warrants will expire 30 days after the public announcement of such trading event.
Kevin Kuykendall, Chairman and CEO of Vivione said "The Loan will be utilized to purchase additional Apogee units, which are the hardware platform for Vivione's RAPID-B technology. This large volume acquisition enables Vivione to achieve a higher volume discount, resulting in decreased costs and reduced delivery timeframes to the end user (16 weeks to almost immediate once a customer places an order). Normally Vivione would have three to four units in inventory at any one time, but Vivione will be utilizing its current Apogee inventory for the AOAC and FSIS certification programs which are underway for our E coli O157 and STEC assays." Mr. Kuykendall went on to say "We're pleased that Mr. Smith has shown further confidence in Vivione's business plan by providing Vivione with the $1,000,000 Loan. The additional funding permits Vivione to have the inventory required for immediate delivery of Apogee units on new orders while not having to utilize the working capital it raised in the $6MM prospectus offering."
Mr. Smith said "I'm pleased to provide Vivione with the $1,000,000 Loan as I believe it will be important for Vivione to provide the Apogee units quickly once a customer makes a decision. Although Vivione is in the early stages of its certification and commercialization program, Vivione has recently demonstrated achievement of some significant milestones, being the collaborative relationships with both the University of Arkansas and Kirkegaard & Perry Laboratories, Inc. I'm confident that if the food safety market realizes the potential benefits the RAPID-B technology can provide, Vivione will be better positioned to realize its business objectives."
On the basis that the Lender is a director of Vivione, the Loan and the proposed issuance of Bonus Warrants are "related party transactions" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101").
Vivione is not required to obtain a formal valuation under MI 61-101 with respect to the Loan because the Loan is a related party transaction described in paragraph (j) of the definition of "related party transaction" in MI 61-101. Section 5.4(1) of MI 61-101 provides that only related party transactions described in paragraphs (a) to (g) of the definition of related party transaction are subject to the formal valuation requirement. Vivione is also exempt from the minority approval requirement of MI 61-101 in respect of the Loan, as pursuant to Section 5.7(1)(f) of MI 61-101, the Loan was negotiated on reasonable commercial terms and does not feature an equity conversion privilege or allow for Vivione to repay the Loan in securities.
The Bonus Warrants will fall under the definition of a related party transaction described in paragraphs (a) to (g) of the definition of related party transaction. Vivione is exempt from the formal valuation requirement in respect of the Bonus Warrants pursuant to Section 5.5(a) of MI 61-101, on the basis that the fair market value of the Bonus Warrants (when issued) will not exceed 25% of the market capitalization of Vivione. Vivione is also exempt from the minority approval requirement of MI 61-101 in respect of the Bonus Warrants pursuant to Section 5.7(1)(a) of MI 61-101 because the fair market value of the Bonus Warrants (when issued) will not exceed 25% of the market capitalization of Vivione.
The Bonus Warrants will be subject to a four-month hold period from the date of issue.
About Vivione
Vivione's business is centered on the commercialization of the RAPID-B technology, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Read more at http://www.stockhouse.com/news/press-releases/2013/09/12/viv…
V.VBI | September 12, 2013
CALGARY, Sept. 12, 2013 /CNW/ - Vivione Biosciences Inc. ("Vivione") (TSXV: VBI) is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Mr. Glenn Smith, a director of Vivione (the "Lender"), whereby the Lender has agreed to provide Vivione with a revolving line of credit facility up to a maximum amount of CDN $1,000,000 for a two-year term (the "Loan"). The Loan will bear interest at a rate of 1% per month on the daily outstanding balance under the Loan, with interest calculated and payable monthly. The Loan is subject to the acceptance of the TSX Venture Exchange.
Pursuant to the terms of the Loan Agreement, Vivione intends to issue and allot to the Lender 400,000 non-transferrable warrants to purchase Class A common shares (the "Bonus Warrants") in the capital of Vivione at an exercise price of $0.35 per share for a two-year term. If the Class A common Shares of Vivione trade on the TSX Venture Exchange at a closing price above $0.42 for 20 consecutive days, the Bonus Warrants will be subject to accelerated expiry, such that the Bonus Warrants will expire 30 days after the public announcement of such trading event.
Kevin Kuykendall, Chairman and CEO of Vivione said "The Loan will be utilized to purchase additional Apogee units, which are the hardware platform for Vivione's RAPID-B technology. This large volume acquisition enables Vivione to achieve a higher volume discount, resulting in decreased costs and reduced delivery timeframes to the end user (16 weeks to almost immediate once a customer places an order). Normally Vivione would have three to four units in inventory at any one time, but Vivione will be utilizing its current Apogee inventory for the AOAC and FSIS certification programs which are underway for our E coli O157 and STEC assays." Mr. Kuykendall went on to say "We're pleased that Mr. Smith has shown further confidence in Vivione's business plan by providing Vivione with the $1,000,000 Loan. The additional funding permits Vivione to have the inventory required for immediate delivery of Apogee units on new orders while not having to utilize the working capital it raised in the $6MM prospectus offering."
Mr. Smith said "I'm pleased to provide Vivione with the $1,000,000 Loan as I believe it will be important for Vivione to provide the Apogee units quickly once a customer makes a decision. Although Vivione is in the early stages of its certification and commercialization program, Vivione has recently demonstrated achievement of some significant milestones, being the collaborative relationships with both the University of Arkansas and Kirkegaard & Perry Laboratories, Inc. I'm confident that if the food safety market realizes the potential benefits the RAPID-B technology can provide, Vivione will be better positioned to realize its business objectives."
On the basis that the Lender is a director of Vivione, the Loan and the proposed issuance of Bonus Warrants are "related party transactions" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101").
Vivione is not required to obtain a formal valuation under MI 61-101 with respect to the Loan because the Loan is a related party transaction described in paragraph (j) of the definition of "related party transaction" in MI 61-101. Section 5.4(1) of MI 61-101 provides that only related party transactions described in paragraphs (a) to (g) of the definition of related party transaction are subject to the formal valuation requirement. Vivione is also exempt from the minority approval requirement of MI 61-101 in respect of the Loan, as pursuant to Section 5.7(1)(f) of MI 61-101, the Loan was negotiated on reasonable commercial terms and does not feature an equity conversion privilege or allow for Vivione to repay the Loan in securities.
The Bonus Warrants will fall under the definition of a related party transaction described in paragraphs (a) to (g) of the definition of related party transaction. Vivione is exempt from the formal valuation requirement in respect of the Bonus Warrants pursuant to Section 5.5(a) of MI 61-101, on the basis that the fair market value of the Bonus Warrants (when issued) will not exceed 25% of the market capitalization of Vivione. Vivione is also exempt from the minority approval requirement of MI 61-101 in respect of the Bonus Warrants pursuant to Section 5.7(1)(a) of MI 61-101 because the fair market value of the Bonus Warrants (when issued) will not exceed 25% of the market capitalization of Vivione.
The Bonus Warrants will be subject to a four-month hold period from the date of issue.
About Vivione
Vivione's business is centered on the commercialization of the RAPID-B technology, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Read more at http://www.stockhouse.com/news/press-releases/2013/09/12/viv…
FDA and Vivione Enter into a New Three-Year Cooperative Research and Development Agreement Aimed at Expanding the Capability of the RAPID-B™ Diagnostic System
LITTLE ROCK, AK, Nov. 19, 2013 - Vivione Biosciences Corporation (TSXV:VBI) today announced a new three-year Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR). The focus of the CRADA is to expand the capability of Vivione's RAPID-B™ diagnostic system.
The Vivione RAPID-B™ system is a revolutionary high-performance diagnostic system for detecting bacterial pathogens. Unlike other systems that look at a gross response of an entire sample to provide information, the RAPID-B™ system looks individually at each bacterium's physical properties (including size, shape, and transparency) and analyzes unique responses to probes and DNA dyes. RAPID-B™ allows the testing of food products in seven hours or less, including sample preparation versus other commercial systems that take up to 48 hours to provide results. Moreover, single shift results are achieved without the need for labor intensive sample preparation steps including centrifugation and immuno-magnetic separation.
The implication for the general public is that RAPID-B™ can yield better and faster micro results than current methods, making food and consumer products safer. "New research contemplated under the CRADA will augment the present RAPID-B™ assays for food safety," said Ted Moskal, Vivione's President and Chief Science Officer. "We are developing new methods that can rapidly identify the pathogens responsible for disease outbreaks beyond food-borne illnesses." Moskal further explained that the new research will expand to include the tiniest disease-causing agents known to man, particularly viruses and prions, for which there are no current detection methods available.
CEO of Arkansas Research Alliance, Jerry Adams said, "I'm very pleased NCTR-FDA has entered into a CRADA with Vivione. The relationship between government research and commercial entities is important for the development of new technologies and employment. The development of better, faster and less expensive diagnostics is both key to maintaining a safer food supply and also to yield better outcomes for identification of infectious disease in clinical settings. The Research Alliance is hopeful that this collaboration will lead to the development of new diagnostics, the growth of biosciences in the state and more knowledge-based jobs."
In both clinical as well as food safety settings, very low pathogen levels can cause human morbidity and mortality, particularly in such susceptible populations as the elderly, children and immune-suppressed individuals. RAPID-B™ has the ability to detect extremely low levels of infectious agents in complex biological matrices, thus potentially increasing early diagnoses, specifically in time-critical situations.
Overall the research under the CRADA will strive to expand the utility of RAPID-B™ to a greater variety of locations and contexts, including field settings and clinical venues. According to Moskal, the goal is to design and test new RAPID-B™ assays capable of real-time detection of diverse pathogens directly from the native sample thus reducing the steps associated with typical sample preparations and yielding faster, simpler and cost-effective diagnostic tests. Arkansas Governor Beebe said, "The State of Arkansas applauds the new Cooperative Research and Development Agreement between the FDA National Center for Toxicological Research and Vivione Biosciences. Public-Private partnerships for research are critical to the development of new products that benefit the public and keep America competitive. The biotech sector is increasingly more important to the generation of knowledge-based jobs. We're so proud that both organizations are located in the state of Arkansas."
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
About KPL
Founded in 1979, KPL was the first company to commercialize affinity purified secondary antibodies, a valuable tool for biological research and in vitro diagnostic testing. Since then KPL has introduced more than 850 reagents and complete assay kits for protein visualization that address the needs of life science researchers. Many leading diagnostic kit manufacturers utilize KPL reagents in a variety of commercially successful diagnostic kits for AIDS, tropical diseases, food testing, and cancer. KPL supports it customers by providing individualized attention, technical service, and customer orders.
For further information, please contact:
Vivione Biosciences Inc.
Kevin Kuykendall
Chief Executive Officer
(214) 886-5733
LITTLE ROCK, AK, Nov. 19, 2013 - Vivione Biosciences Corporation (TSXV:VBI) today announced a new three-year Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR). The focus of the CRADA is to expand the capability of Vivione's RAPID-B™ diagnostic system.
The Vivione RAPID-B™ system is a revolutionary high-performance diagnostic system for detecting bacterial pathogens. Unlike other systems that look at a gross response of an entire sample to provide information, the RAPID-B™ system looks individually at each bacterium's physical properties (including size, shape, and transparency) and analyzes unique responses to probes and DNA dyes. RAPID-B™ allows the testing of food products in seven hours or less, including sample preparation versus other commercial systems that take up to 48 hours to provide results. Moreover, single shift results are achieved without the need for labor intensive sample preparation steps including centrifugation and immuno-magnetic separation.
The implication for the general public is that RAPID-B™ can yield better and faster micro results than current methods, making food and consumer products safer. "New research contemplated under the CRADA will augment the present RAPID-B™ assays for food safety," said Ted Moskal, Vivione's President and Chief Science Officer. "We are developing new methods that can rapidly identify the pathogens responsible for disease outbreaks beyond food-borne illnesses." Moskal further explained that the new research will expand to include the tiniest disease-causing agents known to man, particularly viruses and prions, for which there are no current detection methods available.
CEO of Arkansas Research Alliance, Jerry Adams said, "I'm very pleased NCTR-FDA has entered into a CRADA with Vivione. The relationship between government research and commercial entities is important for the development of new technologies and employment. The development of better, faster and less expensive diagnostics is both key to maintaining a safer food supply and also to yield better outcomes for identification of infectious disease in clinical settings. The Research Alliance is hopeful that this collaboration will lead to the development of new diagnostics, the growth of biosciences in the state and more knowledge-based jobs."
In both clinical as well as food safety settings, very low pathogen levels can cause human morbidity and mortality, particularly in such susceptible populations as the elderly, children and immune-suppressed individuals. RAPID-B™ has the ability to detect extremely low levels of infectious agents in complex biological matrices, thus potentially increasing early diagnoses, specifically in time-critical situations.
Overall the research under the CRADA will strive to expand the utility of RAPID-B™ to a greater variety of locations and contexts, including field settings and clinical venues. According to Moskal, the goal is to design and test new RAPID-B™ assays capable of real-time detection of diverse pathogens directly from the native sample thus reducing the steps associated with typical sample preparations and yielding faster, simpler and cost-effective diagnostic tests. Arkansas Governor Beebe said, "The State of Arkansas applauds the new Cooperative Research and Development Agreement between the FDA National Center for Toxicological Research and Vivione Biosciences. Public-Private partnerships for research are critical to the development of new products that benefit the public and keep America competitive. The biotech sector is increasingly more important to the generation of knowledge-based jobs. We're so proud that both organizations are located in the state of Arkansas."
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
About KPL
Founded in 1979, KPL was the first company to commercialize affinity purified secondary antibodies, a valuable tool for biological research and in vitro diagnostic testing. Since then KPL has introduced more than 850 reagents and complete assay kits for protein visualization that address the needs of life science researchers. Many leading diagnostic kit manufacturers utilize KPL reagents in a variety of commercially successful diagnostic kits for AIDS, tropical diseases, food testing, and cancer. KPL supports it customers by providing individualized attention, technical service, and customer orders.
For further information, please contact:
Vivione Biosciences Inc.
Kevin Kuykendall
Chief Executive Officer
(214) 886-5733
Vivione Biosciences Inc. forms strategic alliance with AriBio, Inc.
LITTLE ROCK, Ark. (TSX-V:VBI) - Vivione Biosciences Inc. (“Vivione”) is pleased to announce the signing of a Memorandum of Understanding (“MOU”) with South Korean biotech company, AriBio, Inc. (“AriBio”). This strategic alliance is anticipated to combine the strengths of Vivione in the areas of rapid diagnostics and its new in silico compound modeling technology (“Molecular Design”) with AriBio’s substantial experience in drug design and testing. The alliance also initiates collaborative development efforts on Vivione’s retail food freshness indicator currently branded as FQI (‘Food Quality Indicator’).
“We see this as a win-win for both companies,” said Vivione’s Chief Executive Officer, Kevin Kuykendall. “AriBio can assist Vivione with accessing the lucrative Asian market and Vivione can help AriBio with companion diagnostics and in silico compound design.”
Building on the Cooperative Research and Development Agreement that was signed with the FDA last year, this partnership marks another milestone for Vivione as being its first prospective alliance with a drug development company. The alliance could benefit AriBio by accelerating the drug development process via specific Vivione intellectual property, Molecular Design, which has the potential to enable accurate computer modeling of the efficacy and potential toxicities of compounds. Vivione expects the alliance will expand their food safety footprint beyond the frontline product, the RAPID-B diagnostic platform, and into companion clinical diagnostics with the potential for growth opportunities in the Asian market.
“We are excited to execute an MOU with Vivione, as they have a number of potentially game changing technologies. This strategic alliance also recognizes AriBio’s capabilities in efficient drug development in various disease areas including psychosis and infection,” according to AriBio Chief Executive Officer Soo-Hyun Sung. “We see our divergent areas of expertise as a strong point in this collaborative effort and we are confident that this will enhance our ability to fulfill current and future technical and business objectives.”
The MOU will also position AriBio as an end user of other various Vivione technologies and as a distributor within Asia. AriBio will garner early visibility and access to Vivione’s RAPID-B diagnostic platform, Molecular Design and Food Quality Indicator product lines, while offering AriBio a first-mover competitive advantage in the rapid diagnostic industry.
One of the most exciting collaborations under the MOU is for Vivione and AriBio to jointly investigate new uses of Vivione’s Molecular Design, the company’s chemical engineering software solution platform, to ensure applications are compliant with local regulatory requirements while adopting global industry best practice. Kevin Kuykendall, Vivione’s CEO stated, “the coupling of Vivione’s new in silico product (Molecular Design) and AriBio’s drug development experience allows both companies to work on a revolutionary system that may save drug development companies millions during the drug development phase. An additional benefit of Molecular Design will be the potential to expedite approvals through regulatory bodies because of Molecular Design’s potential ability to predict subtle nuances in new drug compounds and allowing the drug company to design around these potential side effects”.
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
LITTLE ROCK, Ark. (TSX-V:VBI) - Vivione Biosciences Inc. (“Vivione”) is pleased to announce the signing of a Memorandum of Understanding (“MOU”) with South Korean biotech company, AriBio, Inc. (“AriBio”). This strategic alliance is anticipated to combine the strengths of Vivione in the areas of rapid diagnostics and its new in silico compound modeling technology (“Molecular Design”) with AriBio’s substantial experience in drug design and testing. The alliance also initiates collaborative development efforts on Vivione’s retail food freshness indicator currently branded as FQI (‘Food Quality Indicator’).
“We see this as a win-win for both companies,” said Vivione’s Chief Executive Officer, Kevin Kuykendall. “AriBio can assist Vivione with accessing the lucrative Asian market and Vivione can help AriBio with companion diagnostics and in silico compound design.”
Building on the Cooperative Research and Development Agreement that was signed with the FDA last year, this partnership marks another milestone for Vivione as being its first prospective alliance with a drug development company. The alliance could benefit AriBio by accelerating the drug development process via specific Vivione intellectual property, Molecular Design, which has the potential to enable accurate computer modeling of the efficacy and potential toxicities of compounds. Vivione expects the alliance will expand their food safety footprint beyond the frontline product, the RAPID-B diagnostic platform, and into companion clinical diagnostics with the potential for growth opportunities in the Asian market.
“We are excited to execute an MOU with Vivione, as they have a number of potentially game changing technologies. This strategic alliance also recognizes AriBio’s capabilities in efficient drug development in various disease areas including psychosis and infection,” according to AriBio Chief Executive Officer Soo-Hyun Sung. “We see our divergent areas of expertise as a strong point in this collaborative effort and we are confident that this will enhance our ability to fulfill current and future technical and business objectives.”
The MOU will also position AriBio as an end user of other various Vivione technologies and as a distributor within Asia. AriBio will garner early visibility and access to Vivione’s RAPID-B diagnostic platform, Molecular Design and Food Quality Indicator product lines, while offering AriBio a first-mover competitive advantage in the rapid diagnostic industry.
One of the most exciting collaborations under the MOU is for Vivione and AriBio to jointly investigate new uses of Vivione’s Molecular Design, the company’s chemical engineering software solution platform, to ensure applications are compliant with local regulatory requirements while adopting global industry best practice. Kevin Kuykendall, Vivione’s CEO stated, “the coupling of Vivione’s new in silico product (Molecular Design) and AriBio’s drug development experience allows both companies to work on a revolutionary system that may save drug development companies millions during the drug development phase. An additional benefit of Molecular Design will be the potential to expedite approvals through regulatory bodies because of Molecular Design’s potential ability to predict subtle nuances in new drug compounds and allowing the drug company to design around these potential side effects”.
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Vivione Biosciences Inc. announces closing of the private placement offering with the arkansas venture capital investment trust
Calgary, Alberta: February 20, 2014 - Vivione Biosciences Inc. (“Vivione” or the “Company”) (TSXV: VBI) is pleased to announce that it has successfully completed its previously announced non-brokered private placement offering of 864,000 units at a purchase price of $0.25 per unit for total proceeds of $216,000 (the “Offering”). Each unit consists of one class “A” common share in the capital of the Corporation (“Class A Common Shares”) and one half of one non-transferable Class A Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to purchase one Class A Common Share at an exercise price of $0.35 at any time prior to 4:30 p.m. (Calgary time) on February 19, 2016, subject to accelerated expiry in certain circumstances.
Vivione issued these units to the Arkansas Venture Capital Investment Trust, further strengthening its partnership with the State of Arkansas. "After several years of working together as Vivione grew from an idea to a public entity, we are pleased to now make an equity investment in the company,” stated Gene Eagle, President of the Arkansas Development Finance Authority and Trustee of the Arkansas Venture Capital Investment Trust. “Vivione is the type of business that we wish to stimulate in the State of Arkansas; their success clearly serves as a model for other bioscience and knowledge based companies to follow."
This most recent investment enables Vivione to acquire additional equipment in order to complete key food safety certifications. Moreover, it allows the Company to complete the regulatory approvals which are necessary to deliver RAPID B as a commercially viable solution for various food pathogens (i.e. E. coli O157, STEC’s, Salmonella, Listeria) in 2014.
“We appreciate the great support Gene and his team have provided over the years, especially during our early development years and are pleased to now welcome them as the newest shareholders in the Company,” stated Kevin Kuykendall, Vivione’s CEO. “They have been a great partner and it is exciting to see their commitment and belief grow to the point of investing in the future of Vivione.”
The Common Shares issued pursuant to the Offering are subject to a statutory hold period until June 20, 2014. The Offering is subject to the completion of formal documentation and receipt of regulatory approval, including the conditional approval of the TSX Venture Exchange Inc. Vivione intends to use the net proceeds from the Offering to finance the purchase of additional flow cytometer units for its AOAC certification program.
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Calgary, Alberta: February 20, 2014 - Vivione Biosciences Inc. (“Vivione” or the “Company”) (TSXV: VBI) is pleased to announce that it has successfully completed its previously announced non-brokered private placement offering of 864,000 units at a purchase price of $0.25 per unit for total proceeds of $216,000 (the “Offering”). Each unit consists of one class “A” common share in the capital of the Corporation (“Class A Common Shares”) and one half of one non-transferable Class A Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to purchase one Class A Common Share at an exercise price of $0.35 at any time prior to 4:30 p.m. (Calgary time) on February 19, 2016, subject to accelerated expiry in certain circumstances.
Vivione issued these units to the Arkansas Venture Capital Investment Trust, further strengthening its partnership with the State of Arkansas. "After several years of working together as Vivione grew from an idea to a public entity, we are pleased to now make an equity investment in the company,” stated Gene Eagle, President of the Arkansas Development Finance Authority and Trustee of the Arkansas Venture Capital Investment Trust. “Vivione is the type of business that we wish to stimulate in the State of Arkansas; their success clearly serves as a model for other bioscience and knowledge based companies to follow."
This most recent investment enables Vivione to acquire additional equipment in order to complete key food safety certifications. Moreover, it allows the Company to complete the regulatory approvals which are necessary to deliver RAPID B as a commercially viable solution for various food pathogens (i.e. E. coli O157, STEC’s, Salmonella, Listeria) in 2014.
“We appreciate the great support Gene and his team have provided over the years, especially during our early development years and are pleased to now welcome them as the newest shareholders in the Company,” stated Kevin Kuykendall, Vivione’s CEO. “They have been a great partner and it is exciting to see their commitment and belief grow to the point of investing in the future of Vivione.”
The Common Shares issued pursuant to the Offering are subject to a statutory hold period until June 20, 2014. The Offering is subject to the completion of formal documentation and receipt of regulatory approval, including the conditional approval of the TSX Venture Exchange Inc. Vivione intends to use the net proceeds from the Offering to finance the purchase of additional flow cytometer units for its AOAC certification program.
About Vivione
Vivione’s business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
ab Minute 11:17 - guter Überblick der Firma
Antwort auf Beitrag Nr.: 46.511.881 von Jon_Schnee am 24.02.14 10:57:36[/quote]
Aktien per September 30, 2013 -> in Stück
Class A Shares -> 36,361,382
Class B non-voting Shares -> 29,737,466
Warrants of Vivione -> 14,170,000 (0.33 CAD)
Options -> 1,519,272 (0.23 CAD)
Vollverwässert (inkl. neues PP) ca. 80 Millionen Stück
* 0.20 CAD = 16 MCAD Marktwert
Cash and cash equivalents -> $ 4,080,896
Trade and other payables -> $ 335,730
Current debt -> $ 1,250,786
Verlust 3 Monate -> (734,745)
Verlust 9 Monate -> (1,926,908)
-> Verlust pro Jahr knapp 3 Millionen.
D.h. ca. im Sommer/Herbst brauchen sie neuen Cash.
[/quote]
Aktien per September 30, 2013 -> in Stück
Class A Shares -> 36,361,382
Class B non-voting Shares -> 29,737,466
Warrants of Vivione -> 14,170,000 (0.33 CAD)
Options -> 1,519,272 (0.23 CAD)
Vollverwässert (inkl. neues PP) ca. 80 Millionen Stück
* 0.20 CAD = 16 MCAD Marktwert
Cash and cash equivalents -> $ 4,080,896
Trade and other payables -> $ 335,730
Current debt -> $ 1,250,786
Verlust 3 Monate -> (734,745)
Verlust 9 Monate -> (1,926,908)
-> Verlust pro Jahr knapp 3 Millionen.
D.h. ca. im Sommer/Herbst brauchen sie neuen Cash.
[/quote]
Aktien per September 30, 2013 -> in Stück
Class A Shares -> 36,361,382
Class B non-voting Shares -> 29,737,466
Warrants of Vivione -> 14,170,000 (0.33 CAD)
Options -> 1,519,272 (0.23 CAD)
Vollverwässert (inkl. neues PP) ca. 80 Millionen Stück
* 0.20 CAD = 16 MCAD Marktwert
Cash and cash equivalents -> $ 4,080,896
Trade and other payables -> $ 335,730
Current debt -> $ 1,250,786
Verlust 3 Monate -> (734,745)
Verlust 9 Monate -> (1,926,908)
-> Verlust pro Jahr knapp 3 Millionen.
D.h. ca. im Sommer/Herbst brauchen sie neuen Cash.
[/quote]
[/quote]
Guten Abend
Welche guten Nachrichten (die 1 oder 2 Stück) sollen denn dieses Jahr noch kommen, wenn man eigentlich von einer KE ausgehen muss
Grüße
Class A Shares -> 36,361,382
Class B non-voting Shares -> 29,737,466
Warrants of Vivione -> 14,170,000 (0.33 CAD)
Options -> 1,519,272 (0.23 CAD)
Vollverwässert (inkl. neues PP) ca. 80 Millionen Stück
* 0.20 CAD = 16 MCAD Marktwert
Cash and cash equivalents -> $ 4,080,896
Trade and other payables -> $ 335,730
Current debt -> $ 1,250,786
Verlust 3 Monate -> (734,745)
Verlust 9 Monate -> (1,926,908)
-> Verlust pro Jahr knapp 3 Millionen.
D.h. ca. im Sommer/Herbst brauchen sie neuen Cash.
[/quote]
[/quote]
Guten Abend
Welche guten Nachrichten (die 1 oder 2 Stück) sollen denn dieses Jahr noch kommen, wenn man eigentlich von einer KE ausgehen muss
Grüße
Antwort auf Beitrag Nr.: 46.602.159 von muellerei am 10.03.14 23:25:25Finanzierungn gehöhren bei solchen Klitschen zum Geschäft.
Mögliche Gute News? Patente und Kommerzialsierung.
Mögliche Gute News? Patente und Kommerzialsierung.
Antwort auf Beitrag Nr.: 46.606.495 von muellerei am 11.03.14 15:08:38wie meinst Du: Anteile auf 6 Monatsfrist dritteln?
Chart ist neben einen Spike extrem langweilig
http://www.stockhouse.com/companies/quote/v.vbi/vivione-bios…
hier haben noch nicht viele Anleger Geld gewonnen und verloren.
Chart ist neben einen Spike extrem langweilig
http://www.stockhouse.com/companies/quote/v.vbi/vivione-bios…
hier haben noch nicht viele Anleger Geld gewonnen und verloren.
Vivione Biosciences Inc. Chief Executive Officer interviewed by CEOCFO Magazine
CALGARY, March 25, 2014 /CNW/ - Kevin Kuykendall, Chief Executive Officer of Vivione Biosciences Inc. ("Vivione" or the "Company") (TSXV: VBI) was recently interviewed by Lynn Fosse, Senior Editor of CEOCFO Magazine in response to the Company's developmental successes in the commercialization of the RAPID B platform over the past year. For the full article and additional details, please visit www.vivonebiosciences.com.
Delivering on the key theme of Vivione as an early stage company with a tremendous amount of validity, Mr. Kuykendall spoke of the Company's progress in food safety referencing its "seven years in development with the FDA, its patents, licenses, as well as a solid articulated strategy on how they intend to address the marketplace". He further explained the Company's plans of expanding the current hardware technology into other core areas of opportunity.
"We are starting to see in discussions and demonstrations with large food processing companies that we have several things in our favor" continued Mr. Kuykendall. "There is regulatory pressure that is pushing companies to be more proactive earlier in the processing of food products rather than testing the product at the end of the value cycle." Normally the addition of more testing translates to increased costs, however in this case the food industry is "poised to realize significant cost reductions via the real time diagnostic capability" that Vivione offers. By altering the testing strategy to monitoring all the way back to incoming products through the entire production process, the various stages of processing may be optimized and when bacterial excursions do occur, the line may be stopped before having to destroy inventory. "This approach is a better way of managing Hazard Analysis Critical Control Point (HACCP) regulatory requirements but also more in keeping with the advanced lean manufacturing precepts" Kuykendall explained.
Speaking of cost savings and better inventory control, "When I talk to a lot of the CEOs and CFOs about us, I never talk about the technology. The discussions center more about what economic benefits they can achieve from the RAPID B system. For example, by obtaining near real time results from testing your processing equipment vs. 24-48 hour later, you can reduce your cost of antimicrobials by identifying which machines are problems and which ones aren't. If you are spending $60 million to $70 million dollars a year on antimicrobials and we can potentially shave two to three percent off, that is a big number—particularly when you think of food manufacturers that are working off of single-digit margins."
"Later this year, which is almost a full year in advance of our development plan, we anticipate introducing a new diagnostic capability which will allow the company to expand into clinical and industrial applications. We hope to introduce pharmaceutical sterility tests and testing capabilities in the oil and gas sector; specifically identifying bacteria (known as SRBs or sulfate reducing bacteria) that, if left untreated, can seriously damage the well and its throughput. We already have demonstrated an active tuberculosis test that produces results in less than 30 minutes and have recently signed a cooperative research and development agreement with the FDA to expand on RAPID-B diagnostic capabilities and to develop a test for prion, the causative agent for mad cow disease. We are also moving into the development of new clinical applications which will allow us to quickly identify Staphylococcus and several other key bacteria in a hospital or clinical environment."
One of the most significant advantages about the RAPID-B platform is that enables the performance of various industrial, food safety and clinical tests on the same instrument. Moreover, the RAPID-B platform allows the user to change over to a different test by merely selecting the new test from a 'pull down' menu and using the appropriate bacteria specific reagent kit for testing. The Company's growth strategy is to translate the Company's knowledge gained in the food safety industry into other applications, leveraging its existing hardware platform and focusing on the development of new reagents used to test for individual pathogens.
Mr. Kuykendall concluded with "given the recent enactment of the Food Safety Modernization Act (FSMA) and continuing recall of products, we are relevant to a significant number of food manufacturers needing rapid and accurate test results. We are an early stage company with a tremendous amount of validity - seven years in development with the FDA, patents, licenses and a solid, articulated strategy on how our system saves the end user money and reduces risk. Between food, industrial and clinical, it is a multi-billion dollar diagnostics market. There is an enormous opportunity and we are well positioned to play a major role in it over the coming years."
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system, which is an integrated system of hardware, software and chemical reagents that that tests bacteria in key environments. This technology could have potentially diverse applicability in key food & water safety, clinical, industrial and oil & gas environments, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Read more at http://www.stockhouse.com/news/press-releases/2014/03/25/viv…
CALGARY, March 25, 2014 /CNW/ - Kevin Kuykendall, Chief Executive Officer of Vivione Biosciences Inc. ("Vivione" or the "Company") (TSXV: VBI) was recently interviewed by Lynn Fosse, Senior Editor of CEOCFO Magazine in response to the Company's developmental successes in the commercialization of the RAPID B platform over the past year. For the full article and additional details, please visit www.vivonebiosciences.com.
Delivering on the key theme of Vivione as an early stage company with a tremendous amount of validity, Mr. Kuykendall spoke of the Company's progress in food safety referencing its "seven years in development with the FDA, its patents, licenses, as well as a solid articulated strategy on how they intend to address the marketplace". He further explained the Company's plans of expanding the current hardware technology into other core areas of opportunity.
"We are starting to see in discussions and demonstrations with large food processing companies that we have several things in our favor" continued Mr. Kuykendall. "There is regulatory pressure that is pushing companies to be more proactive earlier in the processing of food products rather than testing the product at the end of the value cycle." Normally the addition of more testing translates to increased costs, however in this case the food industry is "poised to realize significant cost reductions via the real time diagnostic capability" that Vivione offers. By altering the testing strategy to monitoring all the way back to incoming products through the entire production process, the various stages of processing may be optimized and when bacterial excursions do occur, the line may be stopped before having to destroy inventory. "This approach is a better way of managing Hazard Analysis Critical Control Point (HACCP) regulatory requirements but also more in keeping with the advanced lean manufacturing precepts" Kuykendall explained.
Speaking of cost savings and better inventory control, "When I talk to a lot of the CEOs and CFOs about us, I never talk about the technology. The discussions center more about what economic benefits they can achieve from the RAPID B system. For example, by obtaining near real time results from testing your processing equipment vs. 24-48 hour later, you can reduce your cost of antimicrobials by identifying which machines are problems and which ones aren't. If you are spending $60 million to $70 million dollars a year on antimicrobials and we can potentially shave two to three percent off, that is a big number—particularly when you think of food manufacturers that are working off of single-digit margins."
"Later this year, which is almost a full year in advance of our development plan, we anticipate introducing a new diagnostic capability which will allow the company to expand into clinical and industrial applications. We hope to introduce pharmaceutical sterility tests and testing capabilities in the oil and gas sector; specifically identifying bacteria (known as SRBs or sulfate reducing bacteria) that, if left untreated, can seriously damage the well and its throughput. We already have demonstrated an active tuberculosis test that produces results in less than 30 minutes and have recently signed a cooperative research and development agreement with the FDA to expand on RAPID-B diagnostic capabilities and to develop a test for prion, the causative agent for mad cow disease. We are also moving into the development of new clinical applications which will allow us to quickly identify Staphylococcus and several other key bacteria in a hospital or clinical environment."
One of the most significant advantages about the RAPID-B platform is that enables the performance of various industrial, food safety and clinical tests on the same instrument. Moreover, the RAPID-B platform allows the user to change over to a different test by merely selecting the new test from a 'pull down' menu and using the appropriate bacteria specific reagent kit for testing. The Company's growth strategy is to translate the Company's knowledge gained in the food safety industry into other applications, leveraging its existing hardware platform and focusing on the development of new reagents used to test for individual pathogens.
Mr. Kuykendall concluded with "given the recent enactment of the Food Safety Modernization Act (FSMA) and continuing recall of products, we are relevant to a significant number of food manufacturers needing rapid and accurate test results. We are an early stage company with a tremendous amount of validity - seven years in development with the FDA, patents, licenses and a solid, articulated strategy on how our system saves the end user money and reduces risk. Between food, industrial and clinical, it is a multi-billion dollar diagnostics market. There is an enormous opportunity and we are well positioned to play a major role in it over the coming years."
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system, which is an integrated system of hardware, software and chemical reagents that that tests bacteria in key environments. This technology could have potentially diverse applicability in key food & water safety, clinical, industrial and oil & gas environments, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.
Read more at http://www.stockhouse.com/news/press-releases/2014/03/25/viv…
auch hier ein schöner Move 
Vivione (V.VBI) gets set to commercialize its pathogen detection system
Vivione Biosciences Inc. (TSX: V.VBI, Stock Forum) is gearing up to achieve more milestones this year as the company prepares to commercialize the RAPID-B pathogen detection system, which it has been co-developing in the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research in Pine Bluff, Arkansas.
“We officially launched last year after taking the company public on the TSV Venture Exchange and raising $6 million. We expect to begin generating revenue and contacts in the second quarter of this year,’’ said Vivione Chief Executive Officer Kevin Kuykendall in an interview with Stockhouse.
Roughly the size of a desktop computer, RAPID-B consists of hardware, software and wet-ware (reagent test kits) that tests bacteria in key environments including food production, oil field services, and clinical diagnostics.
In food manufacturing, for example, RAPID-B can be used to test for the presence of E.coli 0157 and non-0157 STECs in beef.
A key advantage is that the system can provides test results in seven hours or less. That compares with current rival diagnostic platforms that provide the same test results in 24 hours to five days.
Faster results allows food manufacturers to obtain their test results in near real time for the first time, which in turn allows them to reduce their chemical costs, reduce inventory hold times, and ultimately mitigate their potential recall risks.
“This is our first real year of commercialization,’’ Kuykendall said.
“In May, we anticipate receiving Association of Analytical Communities (AOAC) certification for our e-coli 0157 and non-0157 STECS (an additional six adulterants in E-Coli), which will allow food producers to deploy our equipment for testing up to and including the end product, potentially allowing the company to sell worldwide,’’ he said.
AOAC certification for Salmonella is expected to follow before the end of 2014, and Listeria in mid-2015
Vivione has been developing the RAPID-B system since 2006 in co-operation with FDA-NCTR. To buy one costs about $125,000, orhey can be leased $4,000 a month.
The Vivione CEO attributes the fast test results to the use of a flow cytometer in the RAPID-B system. A flow cytometer is an instrument that utilizes a laser to analyze a sample, optically illuminating every particle in a liquid sample.
The resulting signal from each individual microscope particle is then viewed in real time for a multitude of characteristics.
“Using our flow cytometer, we are able to see the size, shape and refractive index that, when coupled with specific targeting reagents like antibodies, allows us to pick out a specific bacteria amidst a multitude of debris (including other cells and the sample matrix itself) in the sample,’’ he told CEOCFO Magazine recently.
“By examining a multitude of characteristics for each cell, we can confidently identify individual bacteria cells that are viable in the sample,’’ Kuykendall said.
“The RAPID-B system allows us to see a single cell of bacteria, and this sensitivity enables tremendous time savings when compared with competing systems looking for the signal from a multitude of bacteria.’’
While initial revenue is expected to come from the food sector, the company’s other lines of business are expected to include the following:
Clinical diagnostics: Rapid-B system can be used to detect and control infections in hospitals and facilities, speed clinical diagnostics and enable clinical research.
Industrial Microbiology: In the oil industry, for example, the equipment can be used to test for sulphur-reducing bacteria (SRB) in oil and gas wells that would clog up the well and reduce the flow of oil.
The idea is to prevent companies from spending millions of dollars to drill conventional oil or fracking wells and have the bacteria accumulate and either eat through the drill pipe or clog it.
In any discussions with the CEOs and CFOs of potential customers, Kuykendall says he prefers to talk about what the economic benefits of the RAPID-B system rather than the technology itself.
Kuykendall has a deep background in finance. He is a founding member and CEO of ethanol company White Energy, and Health20 (Nutraceuticals). He is experienced in both early stage and start-up fund raising for various ventures.
“My job is to get the company financed, hire the senior management team, set the strategy, get the products commercialized, expand the product pipeline and take the company to the next level,’’ he said.
“We’re on track for the strategy we set in 2013 and feel we’re actually a year ahead in the development of several key areas, including our oil services and clinical offerings. We have several deals in the hopper, and are in the final stages of negotiations which should allow us to start driving revenue in the second quarter of 2014.”
Vivione reported a loss of $756,452 or $0.01 a share in the quarter ended September 30, 2013, when total revenue was $4,750. That compares to a year earlier loss of $386,396 or $0.02, when revenue was $133,306.
In the nine months ended September 30, 2013 the company posted a loss of $2.9 million or 5 cents a share, on revenue of $432,077 that was generated mainly from equipment and product sales to the FDA. That compares to a loss of $1.26 million or $0.06 a share in the equivalent 2012 period, when revenue was $33.
This year, the company hopes to generate up to $2 million in revenue in 2014, marking a 400% increase from 2013 revenues.
By 2015, Vivione expects to have a large footprint in the food sector in North America as well as in Europe. The company believes its clinical applications will begin generating revenue in late 2015 or early 2016.
The stock rose 2.2% to 23 cents on Thursday, leaving a market cap of $8.6 million, based on 37.4 million shares outstanding. The 52-week range is 40 cents and 18 cents.
Disclosure: Vivione Biosciences (V.VBI) is a Stockhouse client. !!!
Read more at http://www.stockhouse.com/news/business-news/2014/03/27/vivi…
Vivione (V.VBI) gets set to commercialize its pathogen detection system
Vivione Biosciences Inc. (TSX: V.VBI, Stock Forum) is gearing up to achieve more milestones this year as the company prepares to commercialize the RAPID-B pathogen detection system, which it has been co-developing in the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research in Pine Bluff, Arkansas.
“We officially launched last year after taking the company public on the TSV Venture Exchange and raising $6 million. We expect to begin generating revenue and contacts in the second quarter of this year,’’ said Vivione Chief Executive Officer Kevin Kuykendall in an interview with Stockhouse.
Roughly the size of a desktop computer, RAPID-B consists of hardware, software and wet-ware (reagent test kits) that tests bacteria in key environments including food production, oil field services, and clinical diagnostics.
In food manufacturing, for example, RAPID-B can be used to test for the presence of E.coli 0157 and non-0157 STECs in beef.
A key advantage is that the system can provides test results in seven hours or less. That compares with current rival diagnostic platforms that provide the same test results in 24 hours to five days.
Faster results allows food manufacturers to obtain their test results in near real time for the first time, which in turn allows them to reduce their chemical costs, reduce inventory hold times, and ultimately mitigate their potential recall risks.
“This is our first real year of commercialization,’’ Kuykendall said.
“In May, we anticipate receiving Association of Analytical Communities (AOAC) certification for our e-coli 0157 and non-0157 STECS (an additional six adulterants in E-Coli), which will allow food producers to deploy our equipment for testing up to and including the end product, potentially allowing the company to sell worldwide,’’ he said.
AOAC certification for Salmonella is expected to follow before the end of 2014, and Listeria in mid-2015
Vivione has been developing the RAPID-B system since 2006 in co-operation with FDA-NCTR. To buy one costs about $125,000, orhey can be leased $4,000 a month.
The Vivione CEO attributes the fast test results to the use of a flow cytometer in the RAPID-B system. A flow cytometer is an instrument that utilizes a laser to analyze a sample, optically illuminating every particle in a liquid sample.
The resulting signal from each individual microscope particle is then viewed in real time for a multitude of characteristics.
“Using our flow cytometer, we are able to see the size, shape and refractive index that, when coupled with specific targeting reagents like antibodies, allows us to pick out a specific bacteria amidst a multitude of debris (including other cells and the sample matrix itself) in the sample,’’ he told CEOCFO Magazine recently.
“By examining a multitude of characteristics for each cell, we can confidently identify individual bacteria cells that are viable in the sample,’’ Kuykendall said.
“The RAPID-B system allows us to see a single cell of bacteria, and this sensitivity enables tremendous time savings when compared with competing systems looking for the signal from a multitude of bacteria.’’
While initial revenue is expected to come from the food sector, the company’s other lines of business are expected to include the following:
Clinical diagnostics: Rapid-B system can be used to detect and control infections in hospitals and facilities, speed clinical diagnostics and enable clinical research.
Industrial Microbiology: In the oil industry, for example, the equipment can be used to test for sulphur-reducing bacteria (SRB) in oil and gas wells that would clog up the well and reduce the flow of oil.
The idea is to prevent companies from spending millions of dollars to drill conventional oil or fracking wells and have the bacteria accumulate and either eat through the drill pipe or clog it.
In any discussions with the CEOs and CFOs of potential customers, Kuykendall says he prefers to talk about what the economic benefits of the RAPID-B system rather than the technology itself.
Kuykendall has a deep background in finance. He is a founding member and CEO of ethanol company White Energy, and Health20 (Nutraceuticals). He is experienced in both early stage and start-up fund raising for various ventures.
“My job is to get the company financed, hire the senior management team, set the strategy, get the products commercialized, expand the product pipeline and take the company to the next level,’’ he said.
“We’re on track for the strategy we set in 2013 and feel we’re actually a year ahead in the development of several key areas, including our oil services and clinical offerings. We have several deals in the hopper, and are in the final stages of negotiations which should allow us to start driving revenue in the second quarter of 2014.”
Vivione reported a loss of $756,452 or $0.01 a share in the quarter ended September 30, 2013, when total revenue was $4,750. That compares to a year earlier loss of $386,396 or $0.02, when revenue was $133,306.
In the nine months ended September 30, 2013 the company posted a loss of $2.9 million or 5 cents a share, on revenue of $432,077 that was generated mainly from equipment and product sales to the FDA. That compares to a loss of $1.26 million or $0.06 a share in the equivalent 2012 period, when revenue was $33.
This year, the company hopes to generate up to $2 million in revenue in 2014, marking a 400% increase from 2013 revenues.
By 2015, Vivione expects to have a large footprint in the food sector in North America as well as in Europe. The company believes its clinical applications will begin generating revenue in late 2015 or early 2016.
The stock rose 2.2% to 23 cents on Thursday, leaving a market cap of $8.6 million, based on 37.4 million shares outstanding. The 52-week range is 40 cents and 18 cents.
Disclosure: Vivione Biosciences (V.VBI) is a Stockhouse client. !!!
Read more at http://www.stockhouse.com/news/business-news/2014/03/27/vivi…
Ich habe Teilgewinne (+305) mitgenommen. Kurs ist wieder zurückgekommen.
Rest lasse ich im Depot
Mentaler SL: 0.18 CAD
Vivione Biosciences Corporate Update
http://www.stockhouse.com/news/press-releases/2014/04/01/viv…
Rest lasse ich im Depot
Mentaler SL: 0.18 CAD
Vivione Biosciences Corporate Update
http://www.stockhouse.com/news/press-releases/2014/04/01/viv…
Vivione Biosciences signs agreement with CMS Technology
LITTLE ROCK, AR, April 15, 2014 /CNW/ - Vivione Biosciences, Inc. (TSX:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, announced the signing of a definitive Purchase Agreement for the RAPID B system from CMS Technology, Inc., ("CMS") a New York-based firm focused on developing and delivering cost-effective, innovative solutions to mitigate pathogen risks in food, packaging and material applications. This agreement brings together two dynamic companies with exciting new technologies in microbial detection in multiple industries.
In addition to immediate revenue generation, this agreement provides Vivione commercial validation of the RAPID-B system by demonstrating its benefits to the market and opening the door for new joint development and promotional opportunities. The system's ability to perform real-time validation studies of its products and services avails CMS immediate opportunities to prove their products efficacy. The RAPID-B system also provides a significant competitive advantage by allowing CMS to provide real time data to its customers versus its competitors who still have to wait up to 48 hours for results.
"This is clearly a win-win for both companies," said Vivione's Chief Executive Officer Kevin Kuykendall. "Vivione benefits by receiving both initial and recurring revenue under this agreement but also the opportunity for the RAPID-B system to be introduced into CMS's food producing customer base. CMS benefits by being able to scale its platform and immediately initiate real-time assessments of its antimicrobial treatments and coverings that the firm is developing."
"We are excited to acquire the RAPID-B system from Vivione," said John Meccia, Chief Executive Officer of CMS. "We surveyed the market quite thoroughly and the RAPID-B system is a superior solution that met our stringent microbial detection requirements. We can now clearly distinguish between live and dead microbes and we have clear enumeration which allows us to show real-time efficacy in our products and services. This cutting edge technology will enhance and accelerate our ability to develop solutions that make the food we eat and the products we use safer, longer lasting and more environmentally friendly."
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in key food & water safety, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.
About CMS Technology
CMS Technology is a specialty chemical company focused on the development and delivery of innovative, microbial resistant solutions for food, packaging and material applications. CMS Technology has developed unique, cost-effective solutions using safe, eco-friendly ingredients that deliver high efficiency without the use of harsh chemicals. For more information, visit www.CMSTechnology.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/04/15/viv…
LITTLE ROCK, AR, April 15, 2014 /CNW/ - Vivione Biosciences, Inc. (TSX:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, announced the signing of a definitive Purchase Agreement for the RAPID B system from CMS Technology, Inc., ("CMS") a New York-based firm focused on developing and delivering cost-effective, innovative solutions to mitigate pathogen risks in food, packaging and material applications. This agreement brings together two dynamic companies with exciting new technologies in microbial detection in multiple industries.
In addition to immediate revenue generation, this agreement provides Vivione commercial validation of the RAPID-B system by demonstrating its benefits to the market and opening the door for new joint development and promotional opportunities. The system's ability to perform real-time validation studies of its products and services avails CMS immediate opportunities to prove their products efficacy. The RAPID-B system also provides a significant competitive advantage by allowing CMS to provide real time data to its customers versus its competitors who still have to wait up to 48 hours for results.
"This is clearly a win-win for both companies," said Vivione's Chief Executive Officer Kevin Kuykendall. "Vivione benefits by receiving both initial and recurring revenue under this agreement but also the opportunity for the RAPID-B system to be introduced into CMS's food producing customer base. CMS benefits by being able to scale its platform and immediately initiate real-time assessments of its antimicrobial treatments and coverings that the firm is developing."
"We are excited to acquire the RAPID-B system from Vivione," said John Meccia, Chief Executive Officer of CMS. "We surveyed the market quite thoroughly and the RAPID-B system is a superior solution that met our stringent microbial detection requirements. We can now clearly distinguish between live and dead microbes and we have clear enumeration which allows us to show real-time efficacy in our products and services. This cutting edge technology will enhance and accelerate our ability to develop solutions that make the food we eat and the products we use safer, longer lasting and more environmentally friendly."
About Vivione
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in key food & water safety, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.
About CMS Technology
CMS Technology is a specialty chemical company focused on the development and delivery of innovative, microbial resistant solutions for food, packaging and material applications. CMS Technology has developed unique, cost-effective solutions using safe, eco-friendly ingredients that deliver high efficiency without the use of harsh chemicals. For more information, visit www.CMSTechnology.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/04/15/viv…
Vivione Biosciences Inc. receives coveted Letter of No Objection (LNO) designation from US Department of Agriculture Food Safety & Inspection Services
Read more at http://www.stockhouse.com/news/press-releases/2014/04/22/viv…
Read more at http://www.stockhouse.com/news/press-releases/2014/04/22/viv…
Anscheinend eine Empfehlung von Danny Deadlock
http://www.stockhouse.com/companies/bullboard/v.vbi/vivione-…
Schöner Kursgewinn. Knapp 100% seit meiner Empfehlung. Ich habe 1/2 mitgenommen. Rest laufenlassen.
http://www.stockhouse.com/companies/bullboard/v.vbi/vivione-…
Schöner Kursgewinn. Knapp 100% seit meiner Empfehlung. Ich habe 1/2 mitgenommen. Rest laufenlassen.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 175 | ||
| 62 | ||
| 56 | ||
| 55 | ||
| 49 | ||
| 45 | ||
| 44 | ||
| 33 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 25 | ||
| 23 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 17 |
